Skip to main content
logo
Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
6.41
-0.06 (-0.93%)
At close: Sep 25, 2026

Interpace Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
36.1438.7346.9340.0431.8433.12
Revenue Growth
-20.48%-17.47%17.21%25.75%-3.86%2.22%
Gross Profit
23.0424.1329.9325.0618.2318.8
Operating Income
4.184.788.113.96-3.84-5.76
Net Income
24.4524.586.241.95-21.96-14.94
Earnings Per Share
4.464.436.972.24-25.91-18.07
EPS Growth
24.12%-36.52%210.60%---

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
2.692.511.463.54.832.67
Total Debt
0.971.185.8611.1916.0910.72
Net Cash (Debt)
1.711.32-4.4-7.69-11.26-8.05
Net Cash Growth
------
Net Cash Per Share
0.310.24-1.40-8.82-13.29-9.74

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
4.465.834.653.79-7.69-8.72
Capital Expenditures
-0.35-0.36-0.88-0.47-0.32-0.35
Free Cash Flow
4.15.483.773.32-8.01-9.07
Free Cash Flow Growth
-2.35%45.23%13.59%---

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
63.75%62.31%63.77%62.58%57.26%56.78%
Operating Margin
11.55%12.35%17.28%9.90%-12.06%-17.41%
Pretax Margin
11.06%9.74%14.81%5.70%-18.33%-23.38%
Profit Margin
67.64%63.45%13.29%4.88%-68.97%-45.12%
FCF Margin
11.36%14.14%8.03%8.29%-25.17%-27.40%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
1.410.221.902.40--
Forward PE
-111.43111.43111.43111.43111.43
P/FCF Ratio
8.661.003.151.41--
PS Ratio
0.980.140.250.120.140.94